Chinese General Practice ›› 2024, Vol. 27 ›› Issue (12): 1431-1437.DOI: 10.12114/j.issn.1007-9572.2023.0598
• Original Research • Previous Articles Next Articles
Received:
2023-09-14
Revised:
2023-11-27
Published:
2024-04-20
Online:
2024-01-23
Contact:
HAN Quanle
通讯作者:
韩全乐
作者简介:
基金资助:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2023.0598
项目 | 类别 | 测评方法 | CVH指标的量化评分(分) |
---|---|---|---|
健康行为 | 饮食状况 | 自述盐、高脂肪食物和茶的摄入量 | 1.盐①<6 g/d:100分;②6~12 g/d:50分;③>12 g/d:0分 2.高脂肪食物①<1次/周:100分;②1~3次/周:50分;③>3次/周:0分 3.饮茶①≥4次/周:100分;②1~3次/周:75分;③1~3次/月:50分;④<1次/月:25分;⑤从不:0分 |
体育活动 | 自我报告的每周体育活动次数 | ①>60 min:100分;②20~60 min:50分;③<20 min:0分 | |
尼古丁暴露 | 自我报告的香烟平均每日使用情况 | ①从不吸烟者:100分;②吸烟者戒烟≥1年:50分;③吸烟者<1支/d:25分;④吸烟者≥1支/d:0分 | |
睡眠时间 | 自我报告平均每晚睡眠时间 | ①7~<9 h:100分;②9~<10 h:90分;③6~<7 h:70分;④5~<6或≥10 h:40分;⑤4~<5 h:20分;⑥<4 h:0分 | |
健康因素 | BMI | 测量并计算:体质量(kg)/身高2(m2) | ①<23.0 kg/m2:100分;②23.0~24.9 kg/m2:75分;③25.0~29.9 kg/m2:50分;④30.0~34.9 kg/m2:25分;⑤≥35.0 kg/m2:0分 |
血脂水平 | 测量血浆总胆固醇和高密度脂蛋白胆固醇指标,并计算非高密度脂蛋白胆固醇 | ①<3.36 mmol/L:100分;②3.36~4.13 mmol/L:60分;③4.14~4.90 mmol/L:40分;④4.91~5.68 mmol/L:20分;⑤≥5.69 mmol/L:0分;如果是治疗后水平,减去20分 | |
血糖水平 | 测量空腹血糖(FBG) | ①无糖尿病史且FBG<5.6 mmol/L:100分;②无糖尿病史且FBG 5.6~6.9 mmol/L:60分;③糖尿病史且FBG<8.6 mmol/L:40分;④糖尿病史且FBG 8.6~10.1 mmol/L:30分;⑤糖尿病史且FBG 10.2~11.6 mmol/L:20分;⑥糖尿病史且FBG 11.7~13.2 mmol/L:10分;⑦糖尿病史且FBG≥13.3 mmol/L:0分 | |
血压水平 | 测量收缩压和舒张压 | ①<120/<80 mmHg:100分;②120~129/<80 mmHg:75分;③130~139/80~89 mmHg:50分;④140~159/90~99 mmHg:25分;⑤>160/≥100 mmHg:0分;如果是治疗后水平,减去20分 |
Table 1 Definition and quantitative scoring of cardiovascular health(Kailuan version of Life's Essential 8)
项目 | 类别 | 测评方法 | CVH指标的量化评分(分) |
---|---|---|---|
健康行为 | 饮食状况 | 自述盐、高脂肪食物和茶的摄入量 | 1.盐①<6 g/d:100分;②6~12 g/d:50分;③>12 g/d:0分 2.高脂肪食物①<1次/周:100分;②1~3次/周:50分;③>3次/周:0分 3.饮茶①≥4次/周:100分;②1~3次/周:75分;③1~3次/月:50分;④<1次/月:25分;⑤从不:0分 |
体育活动 | 自我报告的每周体育活动次数 | ①>60 min:100分;②20~60 min:50分;③<20 min:0分 | |
尼古丁暴露 | 自我报告的香烟平均每日使用情况 | ①从不吸烟者:100分;②吸烟者戒烟≥1年:50分;③吸烟者<1支/d:25分;④吸烟者≥1支/d:0分 | |
睡眠时间 | 自我报告平均每晚睡眠时间 | ①7~<9 h:100分;②9~<10 h:90分;③6~<7 h:70分;④5~<6或≥10 h:40分;⑤4~<5 h:20分;⑥<4 h:0分 | |
健康因素 | BMI | 测量并计算:体质量(kg)/身高2(m2) | ①<23.0 kg/m2:100分;②23.0~24.9 kg/m2:75分;③25.0~29.9 kg/m2:50分;④30.0~34.9 kg/m2:25分;⑤≥35.0 kg/m2:0分 |
血脂水平 | 测量血浆总胆固醇和高密度脂蛋白胆固醇指标,并计算非高密度脂蛋白胆固醇 | ①<3.36 mmol/L:100分;②3.36~4.13 mmol/L:60分;③4.14~4.90 mmol/L:40分;④4.91~5.68 mmol/L:20分;⑤≥5.69 mmol/L:0分;如果是治疗后水平,减去20分 | |
血糖水平 | 测量空腹血糖(FBG) | ①无糖尿病史且FBG<5.6 mmol/L:100分;②无糖尿病史且FBG 5.6~6.9 mmol/L:60分;③糖尿病史且FBG<8.6 mmol/L:40分;④糖尿病史且FBG 8.6~10.1 mmol/L:30分;⑤糖尿病史且FBG 10.2~11.6 mmol/L:20分;⑥糖尿病史且FBG 11.7~13.2 mmol/L:10分;⑦糖尿病史且FBG≥13.3 mmol/L:0分 | |
血压水平 | 测量收缩压和舒张压 | ①<120/<80 mmHg:100分;②120~129/<80 mmHg:75分;③130~139/80~89 mmHg:50分;④140~159/90~99 mmHg:25分;⑤>160/≥100 mmHg:0分;如果是治疗后水平,减去20分 |
变量 | 低CVH组(n=8 407) | 中CVH组(n=73 493) | 高CVH组(n=9 231) | F(χ2)值 | P值 |
---|---|---|---|---|---|
一般资料 | |||||
年龄( | 51.8±10.1 | 51.5±12.2 | 45.6±13.8 | 990.19 | <0.001 |
性别(男/女) | 8 032/375 | 59 762/13 731 | 4 593/4 638 | 6 470.62a | <0.001 |
受教育程度(高中及以上)[名(%)] | 1 383(16.47) | 13 680(18.63) | 3 284(35.60) | 1 544.83a | <0.001 |
家庭人均月收入(>1 000元)[名(%)] | 1 335(15.89) | 9 930(13.52) | 1 635(17.72) | 141.62a | <0.001 |
饮酒史[名(%)] | 5 669(67.46) | 26 554(36.15) | 1 811(19.62) | 4 541.15a | <0.001 |
LE8评分( | 44.12±5.08 | 66.05±7.85 | 83.80±2.89 | 65 625.70 | <0.001 |
饮食 | 34.77±17.10 | 38.55±14.57 | 42.93±15.87 | 661.41 | <0.001 |
体育活动 | 38.47±29.59 | 53.81±23.10 | 61.10±21.50 | 2 174.08 | <0.001 |
睡眠 | 70.30±29.51 | 88.53±20.84 | 96.06±11.54 | 3 648.32 | <0.001 |
烟草暴露 | 15.86±32.91b | 65.74±45.39 | 97.51±13.75 | 8 411.57 | <0.001 |
BMI | 51.62±21.18 | 66.88±23.79 | 92.06±15.11 | 7 378.81 | <0.001 |
Non-HDL-C | 49.17±27.95 | 73.90±27.74 | 93.64±15.53 | 4 862.02 | <0.001 |
FBG | 64.70±30.08 | 86.09±23.28 | 98.14±8.78 | 6 089.39 | <0.001 |
血压 | 28.05±31.00b | 55.46±33.22 | 89.00±15.55 | 8 291.86 | <0.001 |
Table 2 Comparison of general information and LE8 scores among the three groups of subjects
变量 | 低CVH组(n=8 407) | 中CVH组(n=73 493) | 高CVH组(n=9 231) | F(χ2)值 | P值 |
---|---|---|---|---|---|
一般资料 | |||||
年龄( | 51.8±10.1 | 51.5±12.2 | 45.6±13.8 | 990.19 | <0.001 |
性别(男/女) | 8 032/375 | 59 762/13 731 | 4 593/4 638 | 6 470.62a | <0.001 |
受教育程度(高中及以上)[名(%)] | 1 383(16.47) | 13 680(18.63) | 3 284(35.60) | 1 544.83a | <0.001 |
家庭人均月收入(>1 000元)[名(%)] | 1 335(15.89) | 9 930(13.52) | 1 635(17.72) | 141.62a | <0.001 |
饮酒史[名(%)] | 5 669(67.46) | 26 554(36.15) | 1 811(19.62) | 4 541.15a | <0.001 |
LE8评分( | 44.12±5.08 | 66.05±7.85 | 83.80±2.89 | 65 625.70 | <0.001 |
饮食 | 34.77±17.10 | 38.55±14.57 | 42.93±15.87 | 661.41 | <0.001 |
体育活动 | 38.47±29.59 | 53.81±23.10 | 61.10±21.50 | 2 174.08 | <0.001 |
睡眠 | 70.30±29.51 | 88.53±20.84 | 96.06±11.54 | 3 648.32 | <0.001 |
烟草暴露 | 15.86±32.91b | 65.74±45.39 | 97.51±13.75 | 8 411.57 | <0.001 |
BMI | 51.62±21.18 | 66.88±23.79 | 92.06±15.11 | 7 378.81 | <0.001 |
Non-HDL-C | 49.17±27.95 | 73.90±27.74 | 93.64±15.53 | 4 862.02 | <0.001 |
FBG | 64.70±30.08 | 86.09±23.28 | 98.14±8.78 | 6 089.39 | <0.001 |
血压 | 28.05±31.00b | 55.46±33.22 | 89.00±15.55 | 8 291.86 | <0.001 |
分组 | 人数 | 新发房颤[例(%)] | 随访时间(人年) | 发病密度(‰) | 累积发病率(%) |
---|---|---|---|---|---|
低CVH组 | 8 407 | 133(1.58) | 116 853 | 1.140 | 1.73 |
中CVH组 | 73 493 | 883(1.20) | 1 037 067 | 0.851 | 1.28 |
高CVH组 | 9 231 | 72(0.78) | 133 287 | 0.540 | 0.81 |
Table 3 New-onset AF in the three groups of subjects
分组 | 人数 | 新发房颤[例(%)] | 随访时间(人年) | 发病密度(‰) | 累积发病率(%) |
---|---|---|---|---|---|
低CVH组 | 8 407 | 133(1.58) | 116 853 | 1.140 | 1.73 |
中CVH组 | 73 493 | 883(1.20) | 1 037 067 | 0.851 | 1.28 |
高CVH组 | 9 231 | 72(0.78) | 133 287 | 0.540 | 0.81 |
变量 | β | SE | Wald χ2值 | P值 | HR值 | 95%CI |
---|---|---|---|---|---|---|
模型1 | ||||||
LE8评分分组(以低CVH组为参照) | ||||||
中CVH组 | -0.295 | 0.093 | 10.045 | 0.002 | 0.745 | 0.621~0.894 |
高CVH组 | -0.758 | 0.146 | 26.843 | <0.001 | 0.469 | 0.352~0.624 |
LE8评分 | -0.184 | 0.030 | 36.679 | <0.001 | 0.832 | 0.784~0.883 |
模型2 | ||||||
LE8评分分组(以低CVH组为参照) | ||||||
中CVH组 | -0.360 | 0.095 | 14.310 | <0.001 | 0.697 | 0.579~0.841 |
高CVH组 | -0.497 | 0.150 | 10.980 | 0.001 | 0.609 | 0.454~0.816 |
LE8评分 | -0.152 | 0.034 | 20.446 | <0.001 | 0.859 | 0.804~0.918 |
Table 4 Cox proportional hazards regression analysis of the impact of LE8 scoring groups on the risk of new-onset AF
变量 | β | SE | Wald χ2值 | P值 | HR值 | 95%CI |
---|---|---|---|---|---|---|
模型1 | ||||||
LE8评分分组(以低CVH组为参照) | ||||||
中CVH组 | -0.295 | 0.093 | 10.045 | 0.002 | 0.745 | 0.621~0.894 |
高CVH组 | -0.758 | 0.146 | 26.843 | <0.001 | 0.469 | 0.352~0.624 |
LE8评分 | -0.184 | 0.030 | 36.679 | <0.001 | 0.832 | 0.784~0.883 |
模型2 | ||||||
LE8评分分组(以低CVH组为参照) | ||||||
中CVH组 | -0.360 | 0.095 | 14.310 | <0.001 | 0.697 | 0.579~0.841 |
高CVH组 | -0.497 | 0.150 | 10.980 | 0.001 | 0.609 | 0.454~0.816 |
LE8评分 | -0.152 | 0.034 | 20.446 | <0.001 | 0.859 | 0.804~0.918 |
变量 | 模型1 | 模型2 | ||||
---|---|---|---|---|---|---|
P值 | HR值 | 95%CI | P值 | HR值 | 95%CI | |
饮食 | 0.610 | 0.985 | 0.927~1.045 | 0.468 | 0.978 | 0.921~1.039 |
体育活动 | <0.001 | 1.185 | 1.118~1.256 | 0.766 | 0.991 | 0.936~1.050 |
烟草暴露 | 0.049 | 1.063 | 1.000~1.129 | 0.226 | 1.047 | 0.972~1.127 |
睡眠 | <0.001 | 0.895 | 0.847~0.945 | 0.772 | 0.992 | 0.938~1.049 |
BMI | <0.001 | 0.777 | 0.732~0.825 | <0.001 | 0.762 | 0.717~0.809 |
Non-HDL-C | 0.147 | 1.046 | 0.984~1.111 | 0.079 | 1.055 | 0.994~1.121 |
FBG | 0.003 | 0.916 | 0.865~0.970 | 0.391 | 0.976 | 0.922~1.032 |
血压 | <0.001 | 0.683 | 0.645~0.724 | <0.001 | 0.824 | 0.776~0.876 |
Table 5 Cox proportional hazards regression analysis of the impact of LE8 single factor score on the risk of new-onset AF
变量 | 模型1 | 模型2 | ||||
---|---|---|---|---|---|---|
P值 | HR值 | 95%CI | P值 | HR值 | 95%CI | |
饮食 | 0.610 | 0.985 | 0.927~1.045 | 0.468 | 0.978 | 0.921~1.039 |
体育活动 | <0.001 | 1.185 | 1.118~1.256 | 0.766 | 0.991 | 0.936~1.050 |
烟草暴露 | 0.049 | 1.063 | 1.000~1.129 | 0.226 | 1.047 | 0.972~1.127 |
睡眠 | <0.001 | 0.895 | 0.847~0.945 | 0.772 | 0.992 | 0.938~1.049 |
BMI | <0.001 | 0.777 | 0.732~0.825 | <0.001 | 0.762 | 0.717~0.809 |
Non-HDL-C | 0.147 | 1.046 | 0.984~1.111 | 0.079 | 1.055 | 0.994~1.121 |
FBG | 0.003 | 0.916 | 0.865~0.970 | 0.391 | 0.976 | 0.922~1.032 |
血压 | <0.001 | 0.683 | 0.645~0.724 | <0.001 | 0.824 | 0.776~0.876 |
[1] |
|
[2] |
|
[3] |
|
[4] |
|
[5] |
郝玉静,于洁,韩全乐,等. 心房颤动是否会增加新发心肌梗死发病风险?[J]. 中国全科医学,2022,25(17):2121-2126. DOI:10.12114/j.issn.1007-9572.2022.0056.
|
[6] |
|
[7] |
张爱丽,侯旗旗,韩全乐,等. 中国北方人群心房颤动与新发慢性肾脏病发病风险的相关性研究[J]. 中国全科医学,2023,26(36):4521-4526. DOI:10.12114/j.issn.1007-9572.2023.0006.
|
[8] |
|
[9] |
|
[10] |
|
[11] |
|
[12] |
|
[13] |
|
[14] |
|
[15] |
中华医学会心电生理和起搏分会,中国医师协会心律学专业委员会,中国房颤中心联盟心房颤动防治专家工作委员会,等. 心房颤动:目前的认识和治疗建议(2021)[J]. 中华心律失常学杂志,2022,26(1):15-88.
|
[16] |
|
[17] |
|
[18] |
|
[19] |
|
[20] |
中国营养学会肥胖防控分会,中国营养学会临床营养分会,中华预防医学会行为健康分会,等.中国居民肥胖防治专家共识[J]. 中国预防医学杂志,2022,23(5):321-339. DOI:10.16506/j.1009-6639.2022.05.001.
|
[21] |
|
[22] |
|
[23] |
|
[24] |
|
[25] |
|
[26] |
|
[27] |
|
[28] |
|
[29] |
|
[30] |
|
[31] |
|
[32] |
|
[33] |
|
[34] |
|
[1] | SHI Yushuang, WANG Huihua, LI Yan, LU Ping, SONG Wei, PAN Guijun. Analysis of the Effectiveness of Different Atrial Fibrillation Screening Methods in the Community-based Elderly Population [J]. Chinese General Practice, 2024, 27(11): 1316-1319. |
[2] | FAN Caixia, LI Jiao, WEI Yanjin, GUO Dequn, LIU Cunfei, LI Zhengrong, QIU Shi. Influencing Factors of Overanticoagulation at Initial Stage of Warfarin Anticoagulation Therapy in Patients with Atrial Fibrillation [J]. Chinese General Practice, 2024, 27(03): 308-314. |
[3] | WANG Jie, SUN Guozhen, BAO Zhipeng, WANG Lin, GAO Min, LIU Shenxinyu, YU Tianxi, WANG Qin, GAO Rongrong. Development Trajectory and Predictors of Strength-duration Adherence to Home-based Exercise Rehabilitation among Patients with Atrial Fibrillation after Radiofrequency Catheter Ablation: a Longitudinal Study [J]. Chinese General Practice, 2024, 27(02): 168-176. |
[4] | ZHANG Aili, HOU Qiqi, HAN Quanle, ZHANG Boheng, ZHANG Jiawei, CAO Hongxia, ZHANG Chao, CHEN Shuohua, WU Shouling, LI Kangbo. Correlation between Atrial Fibrillation and the Risk of New-onset Chronic Kidney Disease in Northern Chinese Population [J]. Chinese General Practice, 2023, 26(36): 4521-4526. |
[5] | LIU Puqing, CHEN Jingwen, SHOU Zhangxuan. Evaluation of Potentially Inappropriate Medication of Direct Oral Anticoagulant in Hospitalized Elderly Patients with Non-valvular Atrial Fibrillation Based on Beers Criteria [J]. Chinese General Practice, 2023, 26(35): 4388-4393. |
[6] | FEI Sijie, ZHANG Qiang, LIU Fangfang, BAI Lu, SUN Caihong, XIN Caifeng. Correlation between Glycated Hemoglobin Variability and New-onset Atrial Fibrillation in Type 2 Diabetes Patients Combined with Heart Failure with Preserved Ejection Fraction [J]. Chinese General Practice, 2023, 26(26): 3246-3251. |
[7] | SONG Hualong, GAO Ying. Association between Serum Uric Acid and the Risk of Type 2 Diabetes Mellitus: a Population-based Prospective Cohort Study [J]. Chinese General Practice, 2023, 26(15): 1831-1839. |
[8] | YUE Bocheng, HOU Qiqi, HAN Quanle, YANG Bo, WU Zheng, WU Jianmei, CHEN Shuohua, WU Shouling, LI Kangbo. Effect of Atrial Fibrillation on the Risk of New-onset Myocardial Infarction in Hypertensive Population [J]. Chinese General Practice, 2023, 26(14): 1739-1744. |
[9] | ZHANG Ning, HOU Ming, MEI Bo, JIN Weitao, TAN Xiong, YANG Mingchuan, WANG Liang, LIU Yong, LAI Yinglong. Hybrid Ablation: a Future Development Trend in the Management of Atrial Fibrillation [J]. Chinese General Practice, 2023, 26(09): 1136-1145. |
[10] | RUAN Haiyan, LI Liying, ZHANG Muxin, ZHENG Yi, HE Sen. Establishment of a Risk Prediction Model for Thrombotic Events in Chinese Patients with Hypertrophic Cardiomyopathy [J]. Chinese General Practice, 2023, 26(08): 917-926. |
[11] | DUAN Yuanxia, GU Liuna, ZHANG Lei, ZHOU Liting, ZHU Haiying, YANG Chao, CHEN Haiying, GU Xiaoqing, HUANG Jiaoling, GU Jie. Analyze Mastery of Atrial Fibrillation Related Knowledge and Its Influencing Factors among Grassroots Medical Staffs [J]. Chinese General Practice, 2023, 26(07): 869-876. |
[12] | HU Huachao, CHEN Xianya, XIE Siyuan, XIA Zhen, XIAO Hua. Clinical Characteristics and Treatment of Atrial Fibrillation and Heart Failure: a Multicenter Survey [J]. Chinese General Practice, 2023, 26(05): 541-549. |
[13] | TANG Zhijie, SUN Guozhen, WANG Jie, LIU Shenxinyu, BAO Zhipeng, YANG Gang, WANG Lin. Cost-effectiveness Analysis of Early Screening for Atrial Fibrillation: a Review of Recent Advances [J]. Chinese General Practice, 2023, 26(01): 104-112. |
[14] | YU Chao, ZHOU Wei, WANG Tao, ZHU Lingjuan, BAO Huihui, CHENG Xiaoshu. Latest Developments in Wearable Devices for the Screening and Management of Atrial Fibrillation [J]. Chinese General Practice, 2023, 26(01): 113-117. |
[15] | LI Jinyi, LIANG Guicheng, WANG Shirong, LI Shuhu, KE Honghong. Correlation of Markers of Inflammation and Endothelial Injury with Thrombosis in Left Atrium in Patients with Atria Fibrillation [J]. Chinese General Practice, 2022, 25(32): 4018-4022. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||